• FluTrackers.com Inc. does not provide medical advice. Information on this web site is collected from various internet resources, and the FluTrackers board of directors makes no warranty to the safety, efficacy, correctness or completeness of the information posted on this site by any author or poster. The information collated here is for instructional and/or discussion purposes only and is NOT intended to diagnose or treat any disease, illness, or other medical condition. Every individual reader or poster should seek advice from their personal physician/healthcare practitioner before considering or using any interventions that are discussed on this website. By continuing to access this website you agree to consult your personal physican before using any interventions posted on this website, and you agree to hold harmless FluTrackers.com Inc., the board of directors, the members, and all authors and posters for any effects from use of any medication, supplement, vitamin or other substance, device, intervention, etc. mentioned in posts on this website, or other internet venues referenced in posts on this website.
  • We are not asking for any donations. Do not donate to any entity who says they are raising funds for us.

Clinical characteristics, evolution, and treatment-related risk factors for mortality among immunosuppressed patients with influenza A (H1N1) virus ad

tetano

Editor, Senior Moderator
J Crit Care. 2018 Aug 24;48:172-177. doi: 10.1016/j.jcrc.2018.08.017. [Epub ahead of print]
[h=1]Clinical characteristics, evolution, and treatment-related risk factors for mortality among immunosuppressed patients with influenza A (H1N1) virus admitted to the intensive care unit.[/h] Garnacho-Montero J[SUP]1[/SUP], Le?n-Moya C[SUP]2[/SUP], Guti?rrez-Pizarraya A[SUP]3[/SUP], Arenzana-Seisdedos A[SUP]3[/SUP], Vidaur L[SUP]4[/SUP], Guerrero JE[SUP]5[/SUP], Gord?n M[SUP]6[/SUP], Mart?n-Loeches I[SUP]7[/SUP], Rodriguez A[SUP]8[/SUP]; on Behalf GETGAG Study Group.
[h=3]Author information[/h]

[h=3]Abstract[/h] [h=4]PURPOSE:[/h] Information about immunocompromised patients infected with influenza A (H1N1) virus and requiring admission to the ICU is lacking. Our objective was to know the clinical characteristics of these patients and to identify treatment-related variables associated with mortality.
[h=4]MATERIAL AND METHODS:[/h] A prospective multicenter observational cohort study was based on data from a Spanish registry (2009-2015) collected by 148 Spanish ICUs. All patients admitted to the ICU with the diagnosis of influenza A (H1N1) virus infection were included. Immunosuppression was clearly defined. Factors associated with mortality in immunocompromised patients were assessed by conventional logistic regression analysis and by a propensity score (PS) adjusted-multivariable analysis.
[h=4]RESULTS:[/h] Of 1899 patients with influenza A (H1N1) infection, 238 (12.5%) were classified as immunocompromised. Mortality was significantly higher in immunosuppressed patients. Four variables independently associated with mortality were identified: SOFA score, need of vasopressor, use of corticosteroids, and acute renal failure, AKIN 3 stage. In the PS-adjusted model, corticosteroid therapy remained as an independent factor associated with increased mortality (OR 2.25;95%CI, 1.15-4.38;p = 0.017). In the subgroup of hematological patients (n = 141), corticosteroid therapy was also associated with increased mortality (OR 3.12; 95%CI, 1.32-7.41; p = 0.010).
[h=4]CONCLUSION:[/h] Immunocompromised individuals with influenza A (H1N1) admitted to the ICU have a poor outcome. In this population, the use of corticosteroids is strongly discouraged.
Copyright ? 2018 Elsevier Inc. All rights reserved.


PMID: 30216935 DOI: 10.1016/j.jcrc.2018.08.017
 
Back
Top